New Research Collaboration Announced
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) has embarked on an important research collaboration that aims to shed light on the impact of fatigue experienced by individuals diagnosed with craniopharyngioma. This partnership is with the Raymond A. Wood Foundation, a dedicated advocacy group for survivors of specific brain tumors. Together, they strive to enhance the quality of life for those affected by these rare conditions.
Focused on Patient Engagement
David Meeker, M.D., who serves as the Chairman and CEO of Rhythm Pharmaceuticals, expressed enthusiasm for this joint effort. He emphasized the significance of gathering insights directly from patients and their caregivers to enrich the understanding of how craniopharyngioma influences daily lives, particularly concerning fatigue.
Dr. Meeker stated, "Learning directly from patients and caregivers is crucial for advancing our understanding of craniopharyngiomas and fatigue. This information is vital for improving care standards for patients." This sentiment underscores Rhythm’s commitment to involving patients in the research process.
Eligibility for Participation
The collaborative study invites all individuals diagnosed with craniopharyngioma, along with their caregivers, to participate. By gathering a comprehensive array of data, the initiative aims to explore the factors that contribute to fatigue in this unique patient population.
Insights from Advocacy Leaders
Amy Wood, the Founder and Executive Director of the Raymond A. Wood Foundation, shared her optimism about the partnership. She remarked, "We are pleased to join Rhythm in this effort to better understand craniopharyngioma survivors’ experiences with fatigue and factors that may affect it, such as weight gain and daytime sleepiness.” This collaboration aims not only to gather data but also to advocate for improvements in patient care.
How to Get Involved
Those who are interested in participating in the study can find more information and complete surveys by visiting the designated registry website. This initiative serves as a great opportunity for patients to contribute to research that could influence future treatment options significantly.
If you're already a part of the registry, you have the option to log into your account to update your information and engage more deeply with the ongoing research.
About the Organizations
The Raymond A. Wood Foundation is a pioneering organization led by patients and parents, devoted to advocating for those living with craniopharyngioma and similar conditions. Their mission emphasizes driving research and improving treatment outcomes, which aligns seamlessly with the goals of Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals is dedicated to transforming the lives of patients dealing with rare neuroendocrine diseases. Their innovative approach focuses on developing medications for conditions that have historically been either untreatable or inadequately treated. Through collaborations with medical experts globally, Rhythm is leading the way in clinical research for rare diseases, especially those related to the melanocortin-4 receptor pathway.
Corporate and Media Inquiries
For any questions regarding this study or collaboration, David Connolly, Head of Investor Relations and Corporate Communications at Rhythm Pharmaceuticals, is available for contact. For media inquiries, Sheryl Seapy from Real Chemistry can provide additional insights about this groundbreaking collaboration.
Frequently Asked Questions
What is the purpose of the research collaboration?
The collaboration between Rhythm Pharmaceuticals and the Raymond A. Wood Foundation aims to understand the impact of fatigue on patients with craniopharyngioma.
Who can participate in the study?
Individuals diagnosed with craniopharyngioma and their caregivers are eligible to participate in this research study.
How can interested participants get involved?
Participants can get involved by visiting the designated registry website and completing the necessary surveys.
What are the goals of the Raymond A. Wood Foundation?
The foundation aims to advocate for patients and drive research efforts to improve quality of life for craniopharyngioma survivors.
What is Rhythm Pharmaceuticals' focus?
Rhythm specializes in developing therapies for rare neuroendocrine diseases and aims to transform patient lives through innovative treatment solutions.
